VOLUME 39 1991

SUBJECT INDEX

A69024, 911
Acetaldehyde, 55
Acetylcholine, 25, 563, 781, 835
Acetylcholinesterase, 211, 337
Acetylcholinesterase inhibition, 929
ACh levels, 437
ACTH, 765
Active avoidance, 31
Activity, 85, 821, 883
Activity cages, 513
Acute and chronic administration, 313
Acute cocaine administration, 923
Acute opiate withdrawal, 329
Acute stress, 373
Addictive potential, 873
Adenine, 321
Adenosine, 97, 155, 345, 883
5-ADMP, 737
Adrenergic receptor: α_2, 383
α_1-Adrenoceptors, 167, 437
α_2-Adrenoceptors, 167
Aerosol, 265
AF102B, 289
Affect, 509
Aggression (isolation-induced), 729
Aggressive behavior, 167
Aging, 79, 297, 1015
Alaproclate, 25
Alcohol, 5, 443, 513, 531
Alcohol-ethyl, 457
Allodynia, 695
Alpha-2 adrenoceptors, 1015
Alpha$_2$-antagonists, 313
Alzheimer's disease, 287, 563, 841, 991
Amino acids, 115, 205
3-Amino-1,2,4-triazole, 55
9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta-(b)-quinoline monohydrate hydrochloride (NIK-247), 499
Amitriptyline, 553
Ammonia, 115
Amphetamine, 61, 71, 755, 877, 963
Amygdala, 903
Anagrams, 265
Analeptic, 449
Analgesia, 591, 873
Analgesics, 873
Anesthesia, 665
Anhedonia, 895
Animal model, 1, 49, 421
Anorexia, 115, 963
Anosmia, 983
Antagonism, 129
Anticholinergic, 935
Anticholinesterase, 305, 613
Anticonvulsant, 711
Antidepressant, 1, 105, 553, 769
Antiepileptic drugs, 205
Antinociception, 591
Anxiety, 325, 367, 521, 803
Anxiogenic β-carboline, 791
Anxiolysis, 321
Anxiolytic, 275, 367, 977
Apomorphine, 61, 545, 699
Aprophen, 453
Arterial pressure, 1029
Assay method, 495
Associative tolerance, 279
Ataxia, 257
Atenolol, 597
Atipamezole, 1015
Atropine, 453, 613
Aversion, 683
Avoidance learning, 197

Barbital, 705
Barbiturate, 305
Basal forebrain (BF) lesion, 997
Bay K 8644, 325
Behavior, 79, 415, 473, 487, 947
Behavioral effects, 453
Behavioral pattern, 61
Behavioral thermoregulation, 21, 809
Behavioral tolerance, 351
Benactyzine, 453
Benzodiazepine, 129, 559, 671, 711, 859, 903, 1021
Benzodiazepine inverse agonist, 803
Benzodiazepine rebound, 351
Benzodiazepine receptors, 791
Benzodiazepine synergism, 525
Benzodiazepine-GABA$_A$ receptor complex, 553
Beta-adrenoceptors, 597
Beta-endorphin, 201
Bicuculline, 653
Biting, 695
BMY-7378, 729
Body, 305
Body temperature, 249, 535, 1003
Brain histamine, 847
Brain lesions, 1033
Brain regions, 191, 337
Brain temperature, 457
Brain-evoked potential, 889
Bretazenil, 129
Bromocriptine, 367
Bulimia nervosa, 421
Buprenorphine, 487
Buspirone, 275, 729
Butorphanol tartrate, 421

C57BL/6J mice, 821
Caffeine, 97, 525, 883
Calcium channel inhibitors, 743
Calcium channels, 325, 781
Calcium-activated neutral proteases, 495
Calpain, 495
cAMP phosphodiesterase inhibitors, 321
Cancer, 115
Carbamate, 929
β-Carbolines, 559
2β-Carbomethoxy-3β(4-fluorophenyl)tropane, 1011
Cat, 137, 941
Catalase, 55
Catecholamines, 79, 313, 963
Cathine, 549
Caudate nucleus, 619
CCK, 581
Cellular tolerance, 249, 257
Central nervous system depression, 653
Centrally acting cholinesterase inhibitor, 499
Cerebral cortex, 553
Cerebral microdialysis, 619
cGMP, 379
Chemical number 72026-83-6, 161
Chewing behaior, 877
Chloral hydrate, 665
Chlordiazepoxide, 275, 597, 859
Cholecystokinin, 201, 581
Choline acetyltransferase, 337
Choline precursors, 835
Cholinergic, 449
Cholinergic drugs, 49
Cholinesterase inhibitors, 865
Chronic administration, 437
Chronic cocaine administration, 923
Chronic diazepam and plasma protein binding, 395
Chronic flunitrazepam and plasma protein binding, 395
Chronic stress, 293
Chronic treatment, 711
Ciprofloxacin, 587
Circling behavior, 97
$^{36}Cl^-$ uptake, 553
Classical conditioning, 183, 503
Clomipramine, 293
Clonazepam, 671, 1021
Clonidine, 79, 167, 791, 795
Clorgyline, 91
Cocaethylene, 531
Cocaine, 133, 137, 269, 503, 525, 531, 625, 723, 799, 911, 941, 1011
Cocaine analog, 1011
Cocaine recognition sites, 1011
Cognition, 287, 865
Colonic temperature, 37
Common chemical sense, 983
Compensatory response, 279
Concept learning, 829
Conditioned drug effects, 1033
Conditioned place preference, 143, 509, 873, 143
Conditioned taste aversion, 859
Conditioning, 15
Consummatory negative contrast, 803
Consumption, 21
Control of eating, 1025
Convulsions, 109
Copulation, 177
Core temperature, 305, 929
Corpus striatum, 109, 769
Cortex, 437
Corticosterone, 91, 373, 765
Corticosterone response, 149
CPP, 971, 977
Cross-tolerance, 705, 711
Cued navigation, 25
CV 205-502, 465
Cysteic acid, 653
Cysteine sulfinic acid, 653
Cytokine, 535

D1, 449, 465
D2, 449, 465
D1 dopamine antagonists, 799

D1 receptor, 677, 911, 955
D2 agonists, 109
D2 autoreceptor, 545
D2 dopamine antagonists, 799
D2 receptor, 123, 677, 911
D_2 dopamine receptors, 105
D_1 receptors, 769
DA agonist, 367
DA antagonist, 367
[D-Ala^2,Leu^5,Cys^6]-enkephalin (DALCE), 429
Day-old chicks, 717
Delayed matching-to-sample, 79, 817, 935
Delayed nonmatching, 1015
Delayed response, 79
Delta opioid receptor, 429
Dementia, 287, 865
Deoxycorticosterone acetate, 171
2-Deoxy-D-glucose feeding, 429
Dependence, 329, 659
L-Deprenyl, 297
Depression, 1
Deprivation, 211
Deprivation feeding, 429
Desipramine, 43, 167
Desmethyldiazepam, 149
Desmethylimipramine, 1, 293
Development, 883
Dexmedetomidine, 383
Dextromethorphan, 575
DFP, 851
DHPG, 791
Diabetes, 541
Diabetic, 383
Diaphragm, 137
Diazepam, 191, 559, 587, 683, 903
Diazepam dependence in dogs, 395
Diazepam plasma and brain levels, 395
Differential outcomes effect, 817
Dihydropyridines, 743
Diisopropylfluorophosphate, 305
Directed forgetting, 935
Discriminated taste aversion, 859
Discriminative stimulus, 487
Dog, 313
DOI, 605
DOPAC/DA ratio, 1025
Dopamine, 71, 97, 115, 123, 155, 361, 469, 549, 619, 677, 769, 773, 895, 911, 955, 963, 1033
Dopamine and motor function, 955
Dopamine antagonist, 955
Dopamine D_1 receptors, 699
Dopamine D_2 receptors, 699
Dopamine D2 receptor, 177
Dopamine receptor, 465, 517
Dopamine release, 877
Dopaminergic system, 545
Dose-dependent, 143
Dose-response, 841
Doxepine, 293
Drug discrimination, 5, 129, 521, 549, 859, 971
Drug tolerance, 279
DSP-4, 809
Dystonia, 49

Eating, 559, 1003
Ecstasy, 813
EEG, 415, 851
EEG spectral analysis, 665
Electric footshock, 379, 597
Electric footshock-induced fighting behavior, 293
Electrical brain stimulation, 683
Endogenous satiety agent, 161
Endopeptidase, 119
Energy expenditure, 215
Enkephalins, 119
Environmental specificity, 279
Ephedrine, 755
Epilepsy, 415, 683, 825
Epileptiform bursting, 119
Erythrocyte membrane, 443
Escape reaction, 809
Essential tremor, 345
Estrogen/progesterone, 737
Ethanol, 5, 37, 55, 85, 325, 653, 659, 803, 821, 917
Ethanol sensitivity, 457
Excitatory amino acid, 31, 155
Exercise, 337, 821
Explicit unpairing, 279
Exploratory behavior, 877
Eye irritation, 983

Fats, 1025
Feeding, 1003
Feeding behavior, 559
Female rats, 737
Females, 695
Fenfluramine, 91, 549
Fetal alcohol effects, 423
Fetal Alcohol Syndrome (FAS), 389
Fever, 535
FG 7142, 791
Flumazenil, 395
Flunitrazepam dependence in dogs, 395
Flunitrazepam plasma and brain levels, 395
Fluoroquinolones, 587
(^{3}H)-FNZ binding, 379
Food and water consumption, 161
Food intake, 313, 1003
Food restriction, 421
Food reward, 955, 1025
Forced swim test, 373
Forgetting, 437
Free feeding, 429
Free radicals, 649
Frontal cortex, 841

GABA, 345, 473, 653, 765
Gamma-aminobutyric acid, 205
Gangliosides, 825
Gastric transit, 755
Gastric ulcer, 847
Generalization, 129
Genital responses, 177
Gepirone, 729
Glucose, 373
d-Glucose, 383
L-Glutamic acid diethyl ester, 829
Glycine, 31
Gonadectomy, 923
Gray wolf, 559
Grooming, 699
Growth, 883

H_1 and H_2 receptor, 847
Habituation, 903
Haloperidol, 49
Hamster 581
HAS, 5
Heart rate, 15
Heptyl physostigmine, 865
5-HIAA, 787
High pressure neurological syndrome, 773
High-fat feeding, 429
Hippocampal slices, 119
Hippocampus, 105, 437, 689, 781
Holeboard, 373
Homologous acetates, 983
Homologous priming, 517
Housing, 269
5-HT, 729, 787, 813
5-HT antagonism, 367
5-HT receptors, 1021
5-HT_{1A}, 635
5-HT_{1A} receptor agonists, 43
5-HT_{1A} receptors, 407
5-HT_{1C} receptors, 605
5-HT_2 receptors, 407, 605
5-HT_3 receptors, 133, 509
Human, 345
Humans, 613
Hunger, 1003
6-Hydroxydopamine, 677, 1033
4-Hydroxy-3-methamphetamine, 787
Hyperactivity, 71
Hyperalgesia, 695
Hyperbaric conditions, 37
Hyperglycemia, 383
Hypoalgesia, 795
Hypotension, 1029
Hypothalamus, 535, 1003
Hypothermia, 37, 55, 305, 625, 929
Hypoxia, 991

Imipramine, 91, 105, 167, 293, 769
Immobilization, 373
Incentive motivation, 955
Independent ingestion, 955
Individual differences, 877
Indomethacin, 535
Inferior colliculus, 683
Ingestive behavior, 895
Inhibitory G-protein, 383
Insulin deficiency, 383
Intact females, 635
Intensification of abstinence syndrome, 575
Intermediate memory, 717
Intoxicated practice, 917
Intracellular calcium, 641
Intracerebroventricular infusions, 1029
Intraoral catheter, 955
Intrathecal, 591
Intrathecal morphine, 761
Ipsapirone, 729
Isolation, 167
Itch, 695

Kainic acid, 155, 473
Kappa agonist, 215
Ketamine, 575, 829
Ketanserin, 171, 605
K-function, 747
Khat, 549
Kindling, 825

LAS, 5
Lateral head weaving, 671
LD_{50}, 531
Learned tolerance, 249, 257
Learning, 205, 479, 781, 825, 883
Learning enhancement, 31
Lethality, 55

LHRH, 143
Limbic system, 769
Lipid peroxidation, 649
Lipomobilization, 313
Lithium, 91
Locomotion, 269, 321, 513, 877
Locomotor activity, 545, 581, 699, 723, 773, 787, 923
Locus coeruleus, 809
Long-term potentiation, 689
Lordosis, 635, 737
Loss of the righting reflex, 653
LY-163502, 177

M1 selective, 287
Macrophage inflammatory protein-1 (MIP-1), 535
Maharishi-4, 649
Maharishi-5, 649
Male and female Wistar rats, 923
Male rat sexual behavior, 813
Male rats, 143, 605
Male sex behavior, 123
Male sexual behavior, 219
MAO-B inhibitor, 297
Maternal behavior, 71, 201
Maze, 997
MDA, 183, 569, 787
MDL72222, 509
MDMA, 509, 619, 787, 813
Measure stability, 747
Mechanism of death, 625
Medial preoptic nucleus, 737
Median raphe nucleus, 761
Memory, 79, 205, 479, 689
Memory and learning, 997
Memory consolidation, 717
Memory retrieval, 31
Mesolimbic dopamine system, 71
Metabolic tolerance, 249
Metabolism, 383
Methadone, 487
N-Methyl-D-aspartate (NMDA), 479, 977
α-Methyldopamine, 787
α-Methyl-p-tyrosine, 437
Methylenedioxymethamphetamine, 509
3,4-Methylenedioxymethamphetamine, 813
α-Methylepinephrine, 787
α-Methylnorepinephrine, 787
Methyl scopolamine, 689
MHPG, 791
Mianserine, 293
Mice, 167, 197, 321, 531, 769, 865
Microdialysis, 781, 877
Microinjection, 43, 535
Midazolam, 129, 525, 977
Midazolam pharmacokinetics, 351
Midazolam self-administration, 351
Milacemide, 31
MK-801, 479
Monkey, 79
Morphine, 155, 191, 469, 487, 575, 581
Morphine anorexia, 279
Morphine sulfate, 591
Morris Water Maze, 297
Motor activity, 61
Motor impairment, 917
Motor performance, 351, 525
Mouse, 345
Mu opioids, 487
Mucosal chemoreception, 983
Muscarinic receptors, 437, 689
Muscarinic system, 25
Muscimol, 765

NA levels, 437
NA utilization, 293
Naftidrofuryl oxalate, 997
Naloxone, 191, 415, 575, 581, 795
Narcosis, 55
Nasal irritation, 983
Nasal pungency, 983
Natural killer cell cytotoxicity, 361
NBM, 841
Neocortex, 345
Neonatal alcohol exposure, 423
Neonatal analgesia, 389
Neonatal undernutrition, 329
Neuroleptic, 549, 773, 895
Neuropeptide, 201, 581
Neuropeptide Y (NPY), 1003
Neurotoxicity, 569, 787, 813, 963
Neurotransmitters, 115
Nicotine, 197, 545, 929
Nictitating membrane response, 183, 503
Nifedipine, 325, 743
Nigrostriatal dopamine system, 71
Nimodipine, 781
NMDA, 155, 971
NMDA receptor, 31, 513, 829, 947
Nocieption, 541
Noise, 373
Noise avoidance, 821
Nomifensine, 293
Nonhuman primate, 79
Nonreward, 275
Noradrenaline, 795, 809
Noradrenaline release, 191
Noradrenergic drugs, 79
Noradrenergic system, 1015
Norepinephrine, 21, 155, 361, 591, 737, 963
Novelty, 877
Novelty stress, 149
NPC 12626, 977
Nucleus, 619
Nucleus accumbens, 43, 71, 469
Nucleus basalis, 563
Nutrition, 115

Obesity, 963, 1003
Odors, 983
Ofloxacin, 587
6-OHDA, 71
8-OH-DPAT, 729
Olfaction, 983
Olfactory brain, 437
Ontogeny, 517
Ontogeny of dopamine function, 955
Ontogeny of ingestion, 955
Open field, 43, 61, 367
Opiate antinociception, 641
Opiate tolerance, 761
Opiates, 215
Opioid mediation, 389
Opioids, 201, 421, 469
Oral dyskinesia, 677
Oral movements, 49
Organophosphate, 305, 851, 929
Oxiracetam, 197
Oxotremorine, 305, 929
Oxygen, 21
Oxygen consumption, 215
Oxytocin, 219

Pain, 695, 889
Palatability, 895
Paraventricular nucleus, 177, 1003
Partial agonist, 287
Passive avoidance, 31, 563, 835, 841, 997
Pavlovian conditioning, 279
PCP receptors, 155
Penile erection, 123, 177
Pentazocine, 415
Pentobarbital, 249, 257, 705, 977
Pentylenetetrazol, 711
Pentylenetetrazole, 129, 521
Pentylenetetrazol-induced convulsions, 587
Peptides, 1003
Pharmacokinetics, 947
Phencyclidine, 947, 971, 977
Phencyclidine analogs, 947
Phencyclidine metabolism, 947
Phenobarbital, 305, 817
Phenylephrine, 737
Phenylpropanolamine, 755
Phenytoin, 683
Phosphoinositide turnover, 287
Physostigmine, 337, 499, 929
Pigeons, 817, 935
Pigmented vs. albino, 665
Pilocarpine, 109
Pimozide, 895
Pirenperone, 605
Place navigation, 25
Plasma corticosterone, 191, 847
Platform, 211
Positive reinforcement, 955
Postnatal, 883
Prairie voles, 219
Prazosin, 795
Precipitated abstinence, 395
Preclinical study, 873
Predator-prey, 521
Preference, 1025
Prenatal alcohol, 389
Preoptic area, 535
Previous blockade of NMDA receptors, 575
Primate, 123, 991
Prolactin, 91, 373
Propranolol, 345, 597, 717, 795
Prostaglandin, 535
Psychological stress, 191
Psychomotor stimulant and benzodiazepine, 525
Psychopharmacology, 895
PTZ, 825
Punished behavior, 453
Punishment, 597, 977
Pup retrieval, 71
Puromycin, 689
Push-pull perfusion, 1003
PVN, 1003
Pyridostigmine, 613

Quinelorane, 123, 177
Quinolinic acid, 473
Quinpirole, 449, 465, 517
Quipazine, 43
Quisqualate, 155
Quisqualic acid, 563

Rabbit, 183, 503
Raclopride, 465
Radial maze, 287
Radiotelemetry, 457
Rapid eye movement sleep, 211

Rapid tolerance, 917
Rat, 21, 37, 43, 61, 85, 91, 97, 129, 215, 351, 367, 415, 429, 453, 473, 487, 499, 597, 625, 665, 695, 769, 803, 825, 835, 859, 865, 883, 911, 917, 997, 1015
Rat brain, 205
Rat strains, 149, 705
Rearing behavior, 699, 923
Rears, 321
Receptor binding, 287
Receptor supersensitization, 517
Reinforcement, 465
Release, 835
Renin, 171
Respiration, 137
Respiratory control, 941
Respiratory depression, 625
Restraint, 373
Restraint stress, 847
Reward, 509
Rhesus monkeys, 123
Ritanserin, 171, 605, 729
Ro15-1788, 659, 791
Ro15-4513, 803
Rolipram, 321
Rotarod, 257
Rotational behavior, 1033
Route of administration, 581

Salmon calcitonin, 641
Salt appetite, 171
Sarthran, 1029
Satiety mechanism, 1003
SCH 23390, 367, 465, 699, 911
Schedule-induced polydipsia, 351
Schizophrenia, 743
Scopolamine, 25, 689, 835, 935, 997
Scratching, 695
Sedation, 321
Seizure, 625, 941
Selective breeding, 5
Self-administration, 133, 269, 569, 799, 911, 1011
Self-starvation, 85
Self-stimulation, 1, 465
Seminal emission, 177
Sensitization, 903
Sensory, 265
Serotonin, 25, 43, 115, 133, 591, 605, 619, 635, 671, 765, 963, 991
Serotonin syndrome, 407
Serum transferrin, 443
Sex behavior, 737
Sex differences, 923
Sexual behavior, 71, 605, 635
Shaking behavior, 407, 1021
Sham feeding, 1025
Shuttle box, 825
Sialic acid, 443
SKF 38393, 367, 449, 465
Skin jerks, 407
Sleep time, 5, 653
Smoking, 15, 265, 889
Sodium depletion, 171
Sodium valproate, 683
Soman, 305, 851, 929
Somatostatin, 541
Spatial memory, 781
Species-specificity, 769
Spectral analysis of heart rate, 613
Spinal, 155
Spinal cord, 591
Spinal opiate analgesia, 761
Spontaneous behavior, 747
Spontaneously hypertensive rat, 1029
Sprague-Dawley rats, 389, 747
Squirrel monkey, 977, 1011
Startle response, 903
Steroid baseline, 143
Stimulus control, 817
Stimulus properties of drugs, 5
Stimulus salience, 597
Streptozotocin, 383
Stress, 265, 361
Stress-related hormones, 717
Striatum, 97
Subcortex, 437
Subjective response, 889
Substance P, 155, 473, 541, 695
Substantia nigra, 109, 1033
Successive discrimination, 275
Suckling deficits, 423
Sucrose, 895
(−)-Sulpiride, 699
Supersensitivity, 105, 677
Sweet taste, 955, 1025
Switch-off behavior, 683
Sympathomimetics, 755
Synaptosomes, 641

Tachypnea, 941
Tail flick, 761
Tail shock, 373
Tandospirone, 729
Tardive dyskinesia, 49, 743
Taste reactivity, 895
Telemetry, 305
Temperature, 137, 457
Temperature challenge, 457
Temporal memory, 935
Tetrahydroaminoacridine, 499
THA, 563, 841
Theophylline, 345
Thermodynamic activity, 983
Thermogenesis, 21, 755
Thermoregulation, 37, 535, 929, 1003
Thiol proteases, 495
Thresholds, 983
Thromboxane, 535
Time structure, 747
Time, 935
T-maze, 689
Tolerance, 15, 305, 329, 407, 487, 659, 705, 711, 851, 1021
Toxicity, 531
Turnover rate, 671
Two-bottle taste aversion test, 161
Tyrosine, 755

U50,488H, 215
U-78875, 379
Ultrasonic vocalizations, 389
Upper airway, 137
Urethane, 625

Vasoactive intestinal polypeptide, 695
Ventral tegmental area, 469
Ventromedial hypothalamus, 635
Ventromedial nucleus, 737
VER, 851
Vigabatrin, 205
Visual evoked potential, 665
Visual recognition task, 991
Voluntary wheel running, 821

Water intake, 1003
Water maze, 479, 829
Water maze relearning, 563
Weakly reinforced training, 717
Wild running, 683
Withdrawal signs, 659
Working memory, 935
Wy-47,846, 729
Wy-48,723, 729

Yawning, 517
YM-09151-2, 911
Yohimbine, 313, 795

Zacopride, 729
Zetidoline, 367
ZK 93426, 553

AUTHOR INDEX

Aaltonen, M., 563
Abelson, M., 287
Abraini, J. H., 773
Advocat, C., 761
Akselrod, S., 613
Albertson, T. E., 625
Alcalay, M., 613
Ali, S. F., 619
Alkana, R. L., 457
Alling, K., 817
Al-Tajir, G., 109
Amit, Z., 55, 269
Ammassari-Teule, M., 197
Anisman, H., 361
Antoniou, K., 61
Aoki, T., 541
Apfelbaum, M., 215
Appel, N. M., 963
Aragon, C. M. G., 55
Aricioğlu, F., 575
Arjune, D., 429
Armario, A., 373
Arneric, S. P., 337
Asai, S., 499
Aulakh, C. S., 91

Babu, S. R., 337
Bagri, A., 683
Balasch, J., 373
Balster, R. L., 971, 977
Banas, C., 695
Barron, S., 423
Battaglia, M., 197
Battaini, F., 835
Beal, M. F., 473
Beaugé, F., 443
Beckel, M., 559
Becker, A., 825
Becker, H. C., 803
Behm, F., 265

Bejanian, M., 457
Bellinger, L. L., 161
Bender, R., 287
Beninger, R. J., 97
Benjamini, Y., 613
Benson, H. D., 279
Bentley, G., 865
Bergamaschi, S., 835
Berge, O.-G., 37
Bergman, J., 1011
Berlan, M., 313
Berridge, C. W., 877
Betoulle, D., 215
Beyer, C., 695
Bigelow, L. B., 743
Bilsky, E. J., 509
Bitrán, M., 917
Boast, C. A., 287
Bodnar, R. J., 429
Borelli, G., 297
Bourdin, C., 443
Bourguignon, J.-J., 321
Bourre, J. M., 443
Bowen, W. D., 429
Boyle, A. E., 269
Bradberry, C. W., 877
Brandeis, R., 297
Bridges, R. S., 201
Bridson, S., 935
Brigant, L., 215
Britton, D. R., 911
Bruhwyler, J., 367
Brus, R., 517
Bryson, R., 821
Buccafusco, J. J., 79

Caba, M., 695
Cadel, S., 297
Caggiula, A. R., 15
Cai, B., 167, 699
Cain, W. S., 983
Caldarola-Patuszka, M., 635
Callahan, M., 559
Carino, M. A., 449
Carlisle, H. J., 21
Carr, K. L., 883
Carter, C. S., 219
Caskey, N. H., 265
Castellano, C., 197
Cesar, S. S., 581
Chakravarty, A. K., 847
Chamberlin, J. R., 821
Chan, A. W. K., 659
Chance, W. T., 115
Chapman, M. A., 49
Chau, A., 705
Chiu, T. H., 711
Chleide, E., 367
Cho, A. K., 947
Church, A. C., 689
Ciarleglio, A., 531
Clemens, L. G., 737
Clement, J. G., 305, 929
Coen, K. M., 799
Coenen, A. M. L., 415
Cohen, C. A., 329
Commetto-Muñiz, J. E., 983
Contrera, J. F., 963
Corrigal, W. A., 799
Crisp, T., 591
Crowe, S. F., 717
Culp, S., 963
Curzon, P., 911

Dailey, A., 1021
D'Angelo, C. P., 479
Davis, B. L., 737
Dawson, G. R., 865
de Beun, R., 143
de Boer, S. F, 149
de Groot, G., 149
DeLander, G. E., 155
Delarge, J., 367
De Lugt, D., 889
DeNoble, K. F., 991
DeNoble, V. J., 991
Derlet, R. W., 625
De Souza, E. B., 963
Dilsaver, S. C., 553
Dirksen, R., 415
Di Scala, G., 683
Dobrowski, S., 649
Dollison, A., 1021
Dornan, W. A., 813
Draper, F., 865
Droge, M., 635
Dube, S. N., 337
Dufresne, R. L., 1
Dwivedi, C., 649

Eaton, R. C., 177
Ehlers, C. L., 513
Eikelboom, R., 895
Elsworth, J. D., 791
Engberg, G., 809
Enginar, N., 587
Engineer, F. N., 649
Epstein, L. H., 15
Eroğlu, L., 325, 587

Falk, J. L., 351, 525
Felicio, L. F., 201
Ferko, A. P., 653
Finn, D. A., 457
Fischer, J. E., 115
Flexner, J. B., 689
Flexner, L. B., 689
Foderaro, M. A., 581
Foo, H., 795
Frank, C., 119
Freed, W. J., 743

Gadau, C., 825
Galitzky, J., 313
Garcia-Cabrera, I., 37
Gauvin, D. V., 521
Geerts, N. E., 143
Gentili, L., 171
Ghi, P., 437
Giacomo, D., 287
Giaroni, G., 835
Gibbs, J., 1025
Gibbs, M. E., 717
Gil, M., 373
Gill, K., 269
Giroux, M. L., 553
Gong, L., 677
Gorbacheva, E. N., 873
Gormezano, I., 183, 503
Gorzalka, B. B., 605
Gough, B., 619
Govoni, S., 835
Grecksch, G., 825
Greenberg, D., 1025
Griebel, G., 321
Gruen, R. J., 877
Guo, T.-Z., 383
Gutierrez, Y. R., 495

Haass, M., 91
Haertzen, C. A., 723
Hagan, M. M., 421
Hajòs, M., 809
Hale, R. L., 803
Halonen, T., 205
Hansen, S., 71
Harding, J. W., 1029
Harper, R. K., 137, 941
Harper, R. M., 137, 941
Harsing, L., 545
Harthon, C., 71
Hashim, A., 545
Hearn, W. L., 531
Helmstetter, F. J., 903
Herting, R. L., 31
Hijzen, T. H., 859
Hill, J. L., 91
Hiramatsu, M., 947
Holloway, F. A., 521
Holson, R. R., 619
Horita, A., 449
Hsu, F.-L., 787
Hull, E. M., 177
Hull, K. M., 755

Ida, Y., 791
Imamura, L., 699
Irwin, J., 361
Ishii, Y., 499
Ishikawa, K., 499
Iversen, S. D., 865
Izraeli, S., 613

Jackson, W. J., 79
Jäkälä, P., 25
Jansen, E., 143
Järbe, T. U. C., 129
Jerome, C., 1025
Jones, B. L., 457
Jortani, S. A., 977
Josselyn, S. A., 97
Joyal, C. C., 829

Kadar, T., 781
Kafetzopoulos, E., 61
Kalant, H., 705, 917
Kamei, J., 541
Kameyama, T., 947, 997
Kaneko, W., 513
Kant, G. J., 479
Kapitsopoulos, G., 487
Kapon, Y., 297
Kasuya, Y., 541
Katz, J. L., 813
Kebabian, J. W., 911
Kehoe, P., 389
Kelly, S. J., 423
Kerkman, D., 911
Kernan, W. J., 747
Khanna, J. M., 705
Kiraç, R., 325
Kirch, D. G., 743
Kirkpatrick-Steger, K., 183
Klenk-Majewska, B., 293
Knott, V. J., 889
Kobayashi, H., 495
Kogure, M., 499
Koivisto, E., 1015
Komisaruk, B. R., 695
Kong, R. M., 781
Kostowski, W., 43
Kostrzewa, R. M., 517, 677
Koyuncuoğlu, H., 575
Kreeger, T. J., 559
Krimmer, E. C., 1
Kubo, T., 499
Kucharik, R. F., 729
Kulkosky, P. J., 581

Lahtinen, H., 205
Lajtha, A., 545
Lalonde, R., 829
Langan, M. C., 659
Lau, C. E., 351, 525
Leaton, R. N., 903
Lee, H. H., 883
Lee, J. M., 765
Leeb, K., 895
Leone, P., 469
Leong, F. W., 659
Leventer, S., 287
Levin, E. D., 265
Levine, A. S., 559
Levy, A., 781
Levy, M., 1021
Liégeois, J-F., 367
Lieberman, H. R., 781
Lima, L., 671
Löfberg, L., 71
Longoni, A., 835
Lookingland, K. J., 737
Lopez, C. M., 835
Lorens, S. A., 765
Luchetti, G., 171
Lukkarinen, K., 1015
Lumley, L. A., 177

McArthur, S., 287
McKenzie, S. J., 15
McLeod, W. S., 85
McNaughton, N., 275

Mackenzie, R. G., 911
MacKenzie-Taylor, D. R., 249, 257
Madras, B. K., 1011
Magoun, J., 761
Mahalati, K., 219
Maher, T. J., 755
Makhay, M. M., 487
Malatynska, E., 553
Mallick, B. N., 211
Mally, J., 345
Mandenoff, A., 215
Mann, P. E., 201
Mansbach, R. S., 971, 977
Manzanares, J., 737
Markert, L. E., 569
Markowski, V. P., 177
Marshall-Goodell, B., 503
Marti, J., 373
Martin, W. R., 395
Mash, D. C., 531
Massi, M., 171
Matsumoto, K., 167, 699
Matthies, H., 825
Maurer, S., 287
Maze, B., 383

Maze, M., 383
Mehta, O., 287
Melchior, J. C., 215
Melville, L. D., 1025
Mendel, V. E., 161
Mercier, M., 367
Meyer, M. E., 923
Miñano, F. J., 535
Misslin, R., 321
Mitsushio, H., 765
Mizoguchi, K., 191
Molinengo, L., 437
Mollenauer, S., 821
Montanez, S., 635
Montastruc, P., 313
Moore, K. E., 737
Morris, H., 287
Moses, J., 177
Moss, D. E., 421, 495
Moyer, J. A., 287, 729
Mullenix, P. J., 747
Murphy, D. L., 91
Murray, C. E., 1029
Myers, R. D., 535, 1003

Nabeshima, T., 947, 997
Nakajima, S., 465
Nemeroff, C. B., 765
Ng, K. T., 717
Ni, H., 941
Nickel, M., 817
Nowak, G., 769
Nuygen, T., 31

Ogawa, S.-I., 997
Oggero, L., 437
Ohhashi, Y., 541
Ohta, H., 167, 699
Oien, T. T., 379
Okanoya, K., 219
Olson, K. G., 641
O'Regan, N. B., 465
Orsetti, M., 437
Ossowska, G., 293

Pagella, P. G., 865
Pałejko, W., 43
Panickar, K. S., 275
Paris, J. M., 765
Parker, L., 895
Paul, I. A., 769
Pchelintsev, M. V., 873
Peltier, R., 133
Penetrante, F., 659
Pennanen, A., 1015
Perez, R. G., 495
Perkins, K. A., 15
Perni, V. C., 591
Philippens, H. C. H. M., 851
Płaźnik, A., 43
Pluchino, R. S., 407
Pocock, D., 469
Pol, O., 373
Poling, A., 817
Pomerantz, S. M., 123
Pranzatelli, M. R., 407, 1021
Proietti, M. L., 119
Puri, S., 847

Quartermain, D., 31

Rabchenuk, S. A., 903
Rauch, T. M., 781
Ray, A., 847
Rech, R. H., 249, 257
Reid, L. D., 509
Reigel, A. L., 991
Ricaurte, G. A., 813
Riccitelli, A. J., 1
Richard, C. A., 137, 941
Richards-Hill, R., 635
Riekkinen, M., 841
Riekkinen, P., 25, 205, 563, 841, 1015
Riekkinen, P., Jr., 25, 205, 563, 841, 1015
Rijnders, H. J., 129
Riley, E. P., 423
Ritchie, J. C., 765
Roberts, D. C. S., 569
Robinson, T. N., III, 479
Robledo, P., 513
Rockman, G. E., 85
Ronkainen, A., 205
Roscoe, A. K., 1003
Rose, J. E., 265
Rose, S., 531
Rosenberg, H. C., 711
Rostain, J. C., 773
Roth, R. H., 791, 877
Rycroft, W., 865

Sabb, A., 287
Sagratella, S., 119
Saija, A., 171
Salmon, P., 597
Sandner, G., 683
Sansone, M., 197
Santi, A., 935
Sapir, M., 297
Satoh, T., 167
Schanley, D. L., 659
Schechter, M. D., 549
Schellenberg, F., 443
Schenk, S., 133
Schmitz, D. A., 947
Schnur, P., 581
Schrak, L. M., 991
Schwarzkopf, S. B., 553
Scott, A., 883
Scotti de Carolis, A., 119
Seal, U. S., 559
See, R. E., 49
Sen, P., 847
Sershen, H., 545
Sethy, V. H., 379
Seyrig, J. A., 215
Shah, G., 705
Sharma, H. M., 649
Sheu, J., 31
Shibanoki, S., 499
Shimizu, T., 191
Shoemaker, W., 389
Shukitt-Hale, B., 781
Siegel, J., 665
Silverman, P. B., 1029
Sirviö, J., 25, 205, 563, 841, 1015
Sisson, D. F., 665
Skolnick, P., 769
Slangen, J. L., 129, 143
Slikker, W., Jr., 619
Sloan, J. W., 395
Śmiałowski, A., 105
Smith, B. R., 269
Smith, G. P., 955, 1025
Smith, J. A., 15
Somani, S. M., 337
Spanos, L. J., 591
Sparber, S. B., 329
Spealman, R. D., 1011
Speck, C., 821
Spigelman, M. N., 85
Spivak, K., 55
Stafinsky, J. L., 591
Stark, L. G., 625
Starr, M. S., 109
Stefański, R., 43
Steigerwald, E. S., 487
Stillman, M. J., 781
Stone, T. W., 345
Storch, F., 287
Straw, G. M., 743
Suddath, R. L., 743
Svensson, K., 71
Syapin, P. J., 457

Tanaka, M., 191
Tang, M., 351
Terreberry, R. R., 137
Terry, P., 597
Thakkar, M., 211
Thompson, J. T., 177
Tietz, E. I., 711
Tochner, Z., 613
Tomei, C., 773
Tonkiss, J., 329
Trabucchi, M., 835
Trampus, M., 119
Tran, M.-A., 313
Tseng, C.-C., 625
Tsuda, A., 191
Tyrka, A., 955

Uphouse, L., 635
Uram, M., 591
Valentino, D. A., 1
Valjakka, A., 1015
Valsecchi, B., 297
van de Poll, N. E., 143
van der Gugten, J., 149
van der Laan, J. W., 149
Vander Linden, S., 183
Van Haaren, F., 923
Van Luijtelaar, L. J. M., 415
Vanwersch, R. A. P., 851
Vécsi, L., 473
Vigorito, M., 351
Virtanen, R., 1015
Vizcaino, M., 535
Vogel, E., 321

Wagner, J., 531
Wahl, J. J., 155
Wala, E. P., 395
Wallach-Kapon, R., 613
Wallin, E., 71
Watanabe, H., 167, 699
Watson, N. V., 605
Weatherford, S. C., 1025
Weaver, M. F., 591
Weider, J. M., 883
Weill, J., 443
Welch, S. P., 641
Westbrook, 795
Westenberg, I. S., 665
White, S. M., 729
Willetts, J., 977
Williams, J. E. G., 911
Wise, R. A., 469
Witkin, J. M., 453
Witkin, K. M., 453
Witt, D. M., 219
Wolgin, D. L., 279
Wolthuis, O. L., 851
Woudenberg, F., 859
Wozniak, K. M., 91
Wright, J. W., 1029
Wright, W. L., 479
Wyatt, R. J., 743

Yeh, S. Y., 723, 787
Ylinen, A., 205
Yokoo, H., 191
Yoshida, M., 191
Young, A. M., 487
Young, B. J., 903

Zaczek, R., 963
Zalcman, S., 361
Żebrowska-Łupina, I., 293
Zhang, F., 115
Zimmerberg, B., 883
Zohar, J., 91
Zvartau, E. E., 873
Zylan, K. D., 21